ATE457737T1 - Polypeptide zur induktion einer schützenden immunantwort gegen staphylococcus aureus - Google Patents

Polypeptide zur induktion einer schützenden immunantwort gegen staphylococcus aureus

Info

Publication number
ATE457737T1
ATE457737T1 AT04778847T AT04778847T ATE457737T1 AT E457737 T1 ATE457737 T1 AT E457737T1 AT 04778847 T AT04778847 T AT 04778847T AT 04778847 T AT04778847 T AT 04778847T AT E457737 T1 ATE457737 T1 AT E457737T1
Authority
AT
Austria
Prior art keywords
polypeptides
immune response
response against
protective immune
induction
Prior art date
Application number
AT04778847T
Other languages
German (de)
English (en)
Inventor
Annaliesa Anderson
Kathrin Ute Jansen
Rosemarie Kelly
Loren Schultz
Donna Montgomery
William Mcclements
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34107815&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE457737(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE457737T1 publication Critical patent/ATE457737T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04778847T 2003-07-24 2004-07-22 Polypeptide zur induktion einer schützenden immunantwort gegen staphylococcus aureus ATE457737T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48984003P 2003-07-24 2003-07-24
US52011503P 2003-11-14 2003-11-14
PCT/US2004/023523 WO2005009379A2 (en) 2003-07-24 2004-07-22 Polypeptides for inducing a protective immune response against staphylococcus aureus

Publications (1)

Publication Number Publication Date
ATE457737T1 true ATE457737T1 (de) 2010-03-15

Family

ID=34107815

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04778847T ATE457737T1 (de) 2003-07-24 2004-07-22 Polypeptide zur induktion einer schützenden immunantwort gegen staphylococcus aureus

Country Status (23)

Country Link
US (2) US20060177462A1 (enExample)
EP (1) EP1651166B8 (enExample)
JP (1) JP2007502101A (enExample)
KR (1) KR20060065643A (enExample)
AT (1) ATE457737T1 (enExample)
AU (1) AU2004258979B2 (enExample)
BR (1) BRPI0412799A (enExample)
CA (1) CA2532370A1 (enExample)
CY (1) CY1110028T1 (enExample)
DE (1) DE602004025579D1 (enExample)
DK (1) DK1651166T3 (enExample)
ES (1) ES2342778T3 (enExample)
HR (1) HRP20100240T1 (enExample)
IL (1) IL173253A0 (enExample)
IS (1) IS8213A (enExample)
MX (1) MXPA06000854A (enExample)
NO (1) NO20060898L (enExample)
NZ (2) NZ544542A (enExample)
PL (1) PL1651166T3 (enExample)
PT (1) PT1651166E (enExample)
RU (1) RU2337108C2 (enExample)
SI (1) SI1651166T1 (enExample)
WO (1) WO2005009379A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2005079315A2 (en) * 2004-02-18 2005-09-01 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
KR20070085457A (ko) * 2004-10-25 2007-08-27 더 유니버시티 오브 웨스턴 온타리오 스태필로코쿠스 아우레우스의 철에 의해 조절되는 표면결정인자 ＩｓｄＡ, ＩｓｄＢ, 및 ＩｓｄＣ 기재 백신,조성물 및 방법
GB0526038D0 (en) * 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
AU2007210170A1 (en) * 2006-01-27 2007-08-09 Merck Sharp & Dohme Corp. Antigen-binding proteins targeting S. aureus ORF0657n
JP2010516279A (ja) 2007-01-24 2010-05-20 メルク・シャープ・エンド・ドーム・コーポレイション 表皮ブドウ球菌に対する防御免疫応答を誘導するためのポリペプチド
EP1987836B1 (en) * 2007-05-04 2011-12-21 Martin Krönke Protective staphylococcus aureus vaccine based on cell wall-associated proteins
EP2164869A2 (en) * 2007-05-31 2010-03-24 Merck Sharp & Dohme Corp. Antigen-binding proteins targeting s. aureus orf0657n
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
EP2376111A4 (en) 2008-11-26 2013-01-09 Merck Sharp & Dohme POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS
EP3281947B1 (en) 2009-04-03 2020-02-12 The University of Chicago Compositions and methods related to protein a (spa) variants
NZ612315A (en) 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2493510B1 (en) 2009-09-30 2020-07-08 GlaxoSmithKline Biologicals SA Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
PL2493498T3 (pl) 2009-10-30 2017-08-31 Glaxosmithkline Biologicals Sa Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
EP2544709A4 (en) * 2010-03-12 2014-01-08 Univ Pennsylvania METHOD FOR PREVENTING AND TREATING THE COLONIZATION OF STAPHYLOCOCCUS AUREUS AND THEIR INFECTIOUS DISEASES AND DISEASES
ES2655701T3 (es) 2010-07-02 2018-02-21 The University Of Chicago Composiciones y métodos relacionados con variantes de la proteína A (SpA)
WO2012021229A1 (en) 2010-07-13 2012-02-16 Merck Sharp & Dohme Corp. Staphylococcus aureus surface protein sa1789 and protective vaccine based thereon
EP2638058B1 (en) 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
BR112014004782A2 (pt) 2011-09-01 2017-03-21 Novartis Ag formulações adjuvantes de antígenos de staphylococcus aureus
US9527892B2 (en) 2011-10-31 2016-12-27 Merck Sharp & Dohme Corp. Protective vaccine based on Staphylococcus aureus SA2451 protein
MX2014014804A (es) 2012-06-27 2015-02-12 Hoffmann La Roche Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
EP2867253B1 (en) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
EP2872173A4 (en) 2012-07-10 2016-03-23 Merck Sharp & Dohme PROTECTIVE VACCINE BASED ON THE STAPHYLOCOCCUS AUREUS PROTEIN SA2493
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
AU2020273471B2 (en) 2019-05-14 2026-05-07 The University Of Chicago Methods and compositions comprising Staphylococcus protein A (SpA) variants
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
CA2373221A1 (en) * 1999-05-03 2000-11-30 Yashwant M. Deo Human antibodies to staphylococcus aureus
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2002102829A2 (en) * 2001-06-15 2002-12-27 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
ES2322338T3 (es) * 2001-11-12 2009-06-19 Novo Nordisk A/S Purificacion de peptidos por medio de cromatografia de afinidad con iones metalicos.
JP2005532415A (ja) * 2001-12-11 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド スタフィロコッカス・アウレウスエキソポリサッカライド及び方法
US20080050361A1 (en) * 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
EP1998800A2 (en) * 2006-01-18 2008-12-10 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins

Also Published As

Publication number Publication date
EP1651166B8 (en) 2010-05-19
DE602004025579D1 (de) 2010-04-01
JP2007502101A (ja) 2007-02-08
PL1651166T3 (pl) 2010-08-31
US20100247561A1 (en) 2010-09-30
CA2532370A1 (en) 2005-02-03
RU2006105498A (ru) 2006-09-10
WO2005009379A3 (en) 2006-11-30
NZ544542A (en) 2009-01-31
IS8213A (is) 2005-12-30
MXPA06000854A (es) 2006-03-30
DK1651166T3 (da) 2010-05-31
NZ570750A (en) 2009-12-24
IL173253A0 (en) 2006-06-11
NO20060898L (no) 2006-04-24
AU2004258979A1 (en) 2005-02-03
AU2004258979B2 (en) 2007-12-06
KR20060065643A (ko) 2006-06-14
EP1651166B1 (en) 2010-02-17
PT1651166E (pt) 2010-04-23
US20060177462A1 (en) 2006-08-10
EP1651166A4 (en) 2008-03-05
HRP20100240T1 (hr) 2010-09-30
EP1651166A2 (en) 2006-05-03
RU2337108C2 (ru) 2008-10-27
BRPI0412799A (pt) 2006-09-26
WO2005009379A2 (en) 2005-02-03
ES2342778T3 (es) 2010-07-14
CY1110028T1 (el) 2015-01-14
SI1651166T1 (sl) 2010-06-30

Similar Documents

Publication Publication Date Title
DE602004025579D1 (de) Polypeptide zur induktion einer schützenden immunantwort gegen staphylococcus aureus
WO2005079315A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
IN2014CN02050A (enExample)
DE60235761D1 (de) Isoform des vegfs
WO2001064835A8 (en) Novel nucleic acids and polypeptides
BRPI0517493A (pt) polinucleotìdeo isolado, promotor vetor de expressão, célula hospedeira e uso de um polinucleotìdeo
DE602004015995D1 (de) Polypeptid mit verbesserter cytosin-deaminase-aktivität
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
ATE382685T1 (de) Bakteriophagen-lysin
ATE360701T1 (de) Putrescin-n-methyltransferasepromotor
ATE495247T1 (de) Chromoprotein und fluoroproteine
WO2007001361A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
DE60237791D1 (de) Zytokinproteinfamilie
WO2005115113A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2005086663A3 (en) Polypeptides for inducing a protective immune response against staphlococcus aureus
WO2006078680A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2006033918A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
DK2076532T3 (da) Cytokinderivater
DE50213015D1 (de) Lipase-varianten
WO2008115415A8 (en) Polypeptides for inducing a protective immune response against staphylococcus epidermidis
DE60313970D1 (de) Lineare kationische peptide mit fungizider wirksamkeit
DE602007006493D1 (de) Peptide mit proliferationshemmender wirkung
SE0101519D0 (sv) Nucleic ACID
MY137258A (en) Bacterial insecticidal protein
WO2007018482A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1651166

Country of ref document: EP